Lecanemab - Worst Cost-Benefit Ratio in History?
By Patrick Holford In terms of a cost-benefit ratio, Lecanemab has to be one of the worst in history. Reported in the media this week as a ‘breakthrough Alzheimer's medication’ - is this really the case? On the benefit side those in the drug company’s own trial got statistically...
